These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 26502061)

  • 1. Targeting Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MAPKAPK2, MK2): Medicinal Chemistry Efforts To Lead Small Molecule Inhibitors to Clinical Trials.
    Fiore M; Forli S; Manetti F
    J Med Chem; 2016 Apr; 59(8):3609-34. PubMed ID: 26502061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural analysis of an MK2-inhibitor complex: insight into the regulation of the secondary structure of the Gly-rich loop by TEI-I01800.
    Fujino A; Fukushima K; Namiki N; Kosugi T; Takimoto-Kamimura M
    Acta Crystallogr D Biol Crystallogr; 2010 Jan; 66(Pt 1):80-7. PubMed ID: 20057052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokine regulation by MAPK activated kinase 2 in keratinocytes exposed to sulfur mustard.
    Yego EC; Dillman JF
    Toxicol In Vitro; 2013 Oct; 27(7):2067-75. PubMed ID: 23851002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based lead identification of ATP-competitive MK2 inhibitors.
    Barf T; Kaptein A; de Wilde S; van der Heijden R; van Someren R; Demont D; Schultz-Fademrecht C; Versteegh J; van Zeeland M; Seegers N; Kazemier B; van de Kar B; van Hoek M; de Roos J; Klop H; Smeets R; Hofstra C; Hornberg J; Oubrie A
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3818-22. PubMed ID: 21565500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 4-Anilino-6-phenyl-quinoline inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK2).
    Olsson H; Sjö P; Ersoy O; Kristoffersson A; Larsson J; Nordén B
    Bioorg Med Chem Lett; 2010 Aug; 20(16):4738-40. PubMed ID: 20643547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitogen-activated protein kinase-activated protein kinase 2 in neuroinflammation, heat shock protein 27 phosphorylation, and cell cycle: role and targeting.
    Gurgis FM; Ziaziaris W; Munoz L
    Mol Pharmacol; 2014 Feb; 85(2):345-56. PubMed ID: 24296859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Therapeutic Potential of Mitogen-Activated Protein Kinase Activated Protein Kinase 2 (MK2) in Chronic Airway Inflammatory Disorders.
    Singh RK; Najmi AK
    Curr Drug Targets; 2019; 20(4):367-379. PubMed ID: 30112991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-molecular-weight MK2 inhibitors: a tough nut to crack!
    Schlapbach A; Huppertz C
    Future Med Chem; 2009 Oct; 1(7):1243-57. PubMed ID: 21426101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effect of p38 and MK2 kinase inhibitors on the inflammatory and toxicity biomarkers in vitro.
    Singh RK; Diwan M; Dastidar SG; Najmi AK
    Hum Exp Toxicol; 2018 May; 37(5):521-531. PubMed ID: 28629242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A three-step protocol for lead optimization: quick identification of key conformational features and functional groups in the SAR studies of non-ATP competitive MK2 (MAPKAPK2) inhibitors.
    Huang X; Zhu X; Chen X; Zhou W; Xiao D; Degrado S; Aslanian R; Fossetta J; Lundell D; Tian F; Trivedi P; Palani A
    Bioorg Med Chem Lett; 2012 Jan; 22(1):65-70. PubMed ID: 22169260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2,4-Diaminopyrimidine MK2 inhibitors. Part I: Observation of an unexpected inhibitor binding mode.
    Argiriadi MA; Ericsson AM; Harris CM; Banach DL; Borhani DW; Calderwood DJ; Demers MD; Dimauro J; Dixon RW; Hardman J; Kwak S; Li B; Mankovich JA; Marcotte D; Mullen KD; Ni B; Pietras M; Sadhukhan R; Sousa S; Tomlinson MJ; Wang L; Xiang T; Talanian RV
    Bioorg Med Chem Lett; 2010 Jan; 20(1):330-3. PubMed ID: 19919896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protecting the heart through MK2 modulation, toward a role in diabetic cardiomyopathy and lipid metabolism.
    Ruiz M; Coderre L; Allen BG; Des Rosiers C
    Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt B):1914-1922. PubMed ID: 28735097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of the senescence-associated secretory phenotype (SASP) in human fibroblasts using small molecule inhibitors of p38 MAP kinase and MK2.
    Alimbetov D; Davis T; Brook AJ; Cox LS; Faragher RG; Nurgozhin T; Zhumadilov Z; Kipling D
    Biogerontology; 2016 Apr; 17(2):305-15. PubMed ID: 26400758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Theoretical analysis of the binding of potential inhibitors to protein kinases MK2 and MK3.
    Araújo PM; da Silva LP; Esteves da Silva JC
    Med Chem; 2015; 11(6):573-9. PubMed ID: 25665652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Facile synthesis of tetracyclic azepine and oxazocine derivatives and their potential as MAPKAP-K2 (MK2) inhibitors.
    Rao AU; Xiao D; Huang X; Zhou W; Fossetta J; Lundell D; Tian F; Trivedi P; Aslanian R; Palani A
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1068-72. PubMed ID: 22182499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of a novel series of potent MK2 non-ATP competitive inhibitors using 1,2-substituted azoles as cis-amide isosteres.
    Xiao D; Zhu X; Sofolarides M; Degrado S; Shao N; Rao A; Chen X; Aslanian R; Fossetta J; Tian F; Trivedi P; Lundell D; Palani A
    Bioorg Med Chem Lett; 2014 Aug; 24(15):3609-13. PubMed ID: 24913714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of MAPKAPK2/MK2 facilitates DNA replication upon cancer cell treatment with gemcitabine but not cisplatin.
    Li Y; Köpper F; Dobbelstein M
    Cancer Lett; 2018 Aug; 428():45-54. PubMed ID: 29704518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and in vivo activity of MK2 and MK2 substrate-selective p38alpha(MAPK) inhibitors in Werner syndrome cells.
    Davis T; Bagley MC; Dix MC; Murziani PG; Rokicki MJ; Widdowson CS; Zayed JM; Bachler MA; Kipling D
    Bioorg Med Chem Lett; 2007 Dec; 17(24):6832-5. PubMed ID: 17964780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MK2: a novel molecular target for anti-inflammatory therapy.
    Duraisamy S; Bajpai M; Bughani U; Dastidar SG; Ray A; Chopra P
    Expert Opin Ther Targets; 2008 Aug; 12(8):921-36. PubMed ID: 18620516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological functions and role of mitogen-activated protein kinase activated protein kinase 2 (MK2) in inflammatory diseases.
    Singh RK; Najmi AK; Dastidar SG
    Pharmacol Rep; 2017 Aug; 69(4):746-756. PubMed ID: 28582691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.